Skip to main content
SpringerLink
Log in

Alemtuzumab

Treatment refractoriness: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Andersen MA, et al. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. Acta Oncologica 59: 1547-1551, No. 12, Dec 2020. Available from: URL: http://doi.org/10.1080/0284186X.2020.1821913

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab. Reactions Weekly 1856, 24 (2021). https://doi.org/10.1007/s40278-021-96017-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-96017-6

Search

Navigation